Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas.

abstract：:Treosulfan (L-threitol 1,4-bismethanesulfonate, Ovastat) is an alkylating agent and a structural analogue of busulfan. It has been established in the clinical chemotherapy of human ovarian carcinomas for several years and has additionally been shown to be effective against xenografted human breast carcinomas. No other...

journal_title：Cancer chemotherapy and pharmacology

authors： Köpf-Maier P,Sass G

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:To explore the clinical significance of plasma D-dimer increase for transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer (PLC). METHODS:The clinical data of 80 PLC patients who underwent TACE in our hospital from January 2015 to January 2017 were collected, including the plasma...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen X,Chang Z,Liu Z

更新日期：2019-04-01 00:00:00

abstract：OBJECTIVE:We evaluated the efficacy and safety of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced metastatic transitional cell carcinoma of the urothelium. SUBJECTS AND METHODS:The subjects were 12 patients diagnosed with advanced metastatic transitional cell carcinoma of th...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamada Y,Itoh Y,Aoki S,Nakamura K,Taki T,Naruse K,Tobiume M,Zennami K,Katsuda R,Kato Y,Watanabe M,Nishikawa G,Minami M,Nakahira M,Ukai S,Sawada M,Kitamura A,Honda N

更新日期：2009-11-01 00:00:00

abstract：PURPOSE:Anti-epidermal growth factor receptor antibody therapy alone or in combination with irinotecan is recognized as a standard third-line treatment for KRAS wild-type unresectable metastatic colorectal cancer. However, in some cases, it is difficult to administer irinotecan after third-line treatment. Therefore, we...

journal_title：Cancer chemotherapy and pharmacology

authors： Takahashi T,Emi Y,Oki E,Kobayashi K,Tsuji A,Shimokawa M,Tanaka T,Akagi Y,Ogata Y,Baba H,Yoshida K,Natsugoe S,Maehara Y,Kyushu Study Group of Clinical Cancer (KSCC).

更新日期：2016-09-01 00:00:00

abstract：PURPOSE:In clinical trials, the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) administered concomitantly with first-line cytotoxicity chemotherapy failed to confer a survival benefit to patients with non-small-cell lung cancer (NSCLC). The aim of this study was to test whether paclitaxel followe...

journal_title：Cancer chemotherapy and pharmacology

authors： Cheng H,An SJ,Zhang XC,Dong S,Zhang YF,Chen ZH,Chen HJ,Guo AL,Lin QX,Wu YL

更新日期：2011-03-01 00:00:00

abstract：:The cytotoxicity of cisplatin alone and in combination with topotecan (TPT) or SN-38, two novel topoisomerase I (topo I) inhibitors, was determined in a panel of eight well-characterized human solid-tumor cell lines. Interactions between cisplatin and these topo I inhibitors were investigated using three different adm...

journal_title：Cancer chemotherapy and pharmacology

authors： Ma J,Maliepaard M,Nooter K,Boersma AW,Verweij J,Stoter G,Schellens JH

更新日期：1998-01-01 00:00:00

abstract：:Pharmacokinetics studies were performed in ten patients who received VP-16 by intracarotid infusion at 100-300 mg/m2. VP-16 was analyzed by high-pressure liquid chromatography. ESTRIP and NONLIN were used to characterize VP-16 pharmacokinetics. VP-16 disappeared biphasically, with a t1/2 beta of 6.1 +/- 1.4 h; the tot...

journal_title：Cancer chemotherapy and pharmacology

authors： Savaraj N,Feun LG,Lu K,Wallace S,Fields WS,Loo TL

更新日期：1986-01-01 00:00:00

abstract：:Aging influences the disposition and effects of several classes of drugs. Although drug clearance rate is correlated with toxicity for many anticancer drugs, few data have been published concerning the relationship of aging and clearance of chemotherapy. This study was performed to identify any relationship between ag...

journal_title：Cancer chemotherapy and pharmacology

authors： Borkowski JM,Duerr M,Donehower RC,Rowinsky EK,Chen TL,Ettinger DS,Grochow LB

更新日期：1994-01-01 00:00:00

abstract：:Thirty-two evaluable patients with advanced measurable gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and BCNU (FAB). Two complete and fourteen partial responses were observed, with an overall response rate of 50%. The median duration of response was 10 months, and the median sur...

journal_title：Cancer chemotherapy and pharmacology

authors： Lopez M,Perno CF,Di Lauro L,Papaldo P

更新日期：1984-01-01 00:00:00

abstract：:The toxic effect of 3'-deoxyadenosine N1-oxide (3'-dANO) on mice, on their different organs, and on Ehrlich ascites tumor cells was studied. In both healthy and tumour-bearing animals, the lethal dose for 10% of the mice receiving i.p. injections (LD10) of 3'-dANO was estimated to be about 300 mg/kg x 4 days in one mo...

journal_title：Cancer chemotherapy and pharmacology

authors： Svendsen KR,Overgaard-Hansen K,Frederiksen S,Engelholm SA,Pedersen NT,Vindeløv LL

更新日期：1992-01-01 00:00:00

abstract：:A total of 26 evaluable patients presenting with advanced or metastatic squamous-cell carcinoma of the esophagus were entered in a phase II trial to assess the single-agent activity of etoposide. Etoposide was given at a dose of 200 mg/m2 on 3 consecutive days every 3 weeks. Five patients (19%) achieved a partial resp...

journal_title：Cancer chemotherapy and pharmacology

authors： Harstrick A,Bokemeyer C,Preusser P,Köhne-Wömpner CH,Meyer HJ,Stahl M,Knipp H,Schmoll HJ,Wilke H

更新日期：1992-01-01 00:00:00

abstract：:The rate of reaction of monochlorobimane with glutathione (GSH) was measured in native human mammary MCF-7 adenocarcinoma cells (MCF-7wt) and sublines displaying resistance to 4-hydroperoxycyclophosphamide (MCF-7hc) and adriamycin (MCF-7adr) prior to examination by epifluorescence and confocal microscopy. After a 60-m...

journal_title：Cancer chemotherapy and pharmacology

authors： Millis KK,Lesko SA,Gamcsik MP

更新日期：1997-01-01 00:00:00

abstract：:We have developed and validated a selective analytical procedure, based on ion-exchange normal-phase liquid chromatography with fluorescence detection and liquid-liquid extraction, for the analysis of vinblastine (VBL) in biological matrices. The assay is suitable for the determination of the parent compound and its m...

journal_title：Cancer chemotherapy and pharmacology

authors： van Tellingen O,Beijnen JH,Nooijen WJ,Bult A

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:The addition of cetuximab to triplet chemotherapy can increase treatment efficacy for patients with metastatic colorectal cancer (mCRC). We explored the dose-limiting toxicity and feasibility of a triweekly capecitabine, oxaliplatin, irinotecan, plus cetuximab (XELOXIRI plus cetuximab) regimen in patients with ...

journal_title：Cancer chemotherapy and pharmacology

authors： Sato Y,Hirakawa M,Ohnuma H,Takahashi M,Okamoto T,Okamoto K,Miyamoto H,Muguruma N,Furuhata T,Takemasa I,Kato J,Takayama T

更新日期：2017-12-01 00:00:00

abstract：PURPOSE:Irinotecan-induced gut toxicity is mediated in part by Toll-Like receptor 4 (TLR4) signalling. The primary purpose of this preclinical study was to determine whether blocking TLR4 signalling by administering (-)-naloxone, a TLR4 antagonist, would improve irinotecan-induced gut toxicity. Our secondary aim was to...

journal_title：Cancer chemotherapy and pharmacology

authors： Coller JK,Bowen JM,Ball IA,Wardill HR,van Sebille YZ,Stansborough RL,Lightwala Z,Wignall A,Shirren J,Secombe K,Gibson RJ

更新日期：2017-02-01 00:00:00

abstract：PURPOSE:The prognosis of gastroesophageal cancer is poor, and current regimens are associated with limited efficacy. The purpose of this study was to explore the safety and preliminary efficacy of docetaxel, oxaliplatin plus capecitabine for advanced cancer of the stomach or the gastroesophageal junction (GEJ). Seconda...

journal_title：Cancer chemotherapy and pharmacology

authors： Deenen MJ,Meulendijks D,Boot H,Legdeur MC,Beijnen JH,Schellens JH,Cats A

更新日期：2015-12-01 00:00:00

abstract：PURPOSE:High-dose methotrexate (HD-MTX) is widely used in the treatment of non-Hodgkin lymphoma (NHL), but the pharmacokinetic properties of HD-MTX in Chinese adult patients with NHL have not yet been established through an approach that integrates genetic covariates. The purposes of this study were to identify both ph...

journal_title：Cancer chemotherapy and pharmacology

authors： Yang L,Wu H,de Winter BCM,Sheng CC,Qiu HQ,Cheng Y,Chen J,Zhao QL,Huang J,Jiao Z,Xie RX

更新日期：2020-05-01 00:00:00

abstract：:GR63178A is the second pentacyclic pyrroloquinone to enter clinical trials as an anticancer drug. We developed a reversed-phase, gradient-elution high-performance liquid chromatography (HPLC) method along with a Bond Elut C2 mini-column sample-preparation technique for the analysis of GR63178A, its 9-hydroxy-metabolit...

journal_title：Cancer chemotherapy and pharmacology

authors： Cummings J,French RC,MacLellan A,Smyth JF

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:To compare the response rates, toxicities and survival durations of elderly patients (70 years of age or more) with those of younger patients (less than 70 years of age) with non-small-cell lung cancer (NSCLC) treated with cisplatin-based chemotherapy. PATIENTS AND METHODS:We analyzed retrospectively the data ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kubota K,Furuse K,Kawahara M,Kodama N,Ogawara M,Takada M,Masuda N,Negoro S,Matsui K,Takifuji N,Kudoh S,Kusunoki Y,Fukuoka M

更新日期：1997-01-01 00:00:00

abstract：:This phase I study was carried out to determine the maximal tolerated dose of carboplatin (Car) together with a fixed dose of etoposide (E) and to recommend the optimal dose for a phase II study. The dose of E was 100 mg/m2 given i.v. on days 1-3, and the starting dose of Car was 200 mg/m2 given i.v. on day 1. The dos...

journal_title：Cancer chemotherapy and pharmacology

authors： Liippo K,Nikkanen V,Heinonen E

更新日期：1990-01-01 00:00:00

abstract：:DON (6-diazo-5-oxo-L-norleucine), a glutamine antagonist, has been subjected to limited clinical trials since 1957. Use of the drug in adults has been curtailed due to sparse reports of effectiveness as well as its dose-limiting toxicities, i.e., severe nausea, vomiting and mucositis. In earlier studies, children give...

journal_title：Cancer chemotherapy and pharmacology

authors： Sullivan MP,Nelson JA,Feldman S,Van Nguyen B

更新日期：1988-01-01 00:00:00

abstract：BACKGROUND:The objective of this study was to evaluate the efficacy and safety of concurrent immune checkpoint inhibitor therapy and radiotherapy (immunoradiotherapy) in patients with metastatic melanoma after progression on nivolumab. PATIENTS AND METHODS:A retrospective review was performed on 16 consecutive patient...

journal_title：Cancer chemotherapy and pharmacology

authors： Nomura M,Otsuka A,Yoshimura M,Nonomura Y,Kaku Y,Matsumoto S,Muto M

更新日期：2018-05-01 00:00:00

abstract：PURPOSE:The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer. METHODS:A total...

journal_title：Cancer chemotherapy and pharmacology

authors： Pilancı KN,Saglam S,Okyar A,Yucel S,Pala-Kara Z,Ordu C,Namal E,Ciftci R,Iner-Koksal U,Kaytan-Saglam E

更新日期：2016-07-01 00:00:00

abstract：:The present study deals with the influence of some bis(eta 5-cyclopentadienyl)titanium(IV) (titanocene) complexes, mainly represented by titanocene dichloride, on the development of several human gastrointestinal (GI) carcinomas (one stomach, seven colon, four sigmoid, and two rectal adenocarcinomas), all xenografted ...

journal_title：Cancer chemotherapy and pharmacology

authors： Köpf-Maier P

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:HER2-targeted therapy with trastuzumab and (CF/X) prolonged overall survival (OS) in metastatic HER2neu+ gastric carcinoma (GC). Lapatinib inhibits both EGFR and HER2neu. We investigated the efficacy and safety of lapatinib with epirubicin (E) + CF/X in GC according to HER2neu and EGFR status. METHODS:Tumors f...

journal_title：Cancer chemotherapy and pharmacology

authors： Moehler M,Schad A,Maderer A,Atasoy A,Mauer ME,Caballero C,Thomaidis T,John JMM,Lang I,Van Cutsem E,Freire J,Lutz MP,Roth A,EORTC Gastrointestinal Tract Cancer Group.

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:Few clinical phase II studies using non-platinum doublet as adjuvant chemotherapy following complete resection of non-small-cell lung cancer (NSCLC) have been published, so this clinical study was designed to evaluate the toxicity profile and efficacy of the non-platinum doublet of docetaxel (DOC) + gemcitab...

journal_title：Cancer chemotherapy and pharmacology

authors： Kawamura M,Eguchi K,Izumi Y,Yamato Y,Koike T,Sakaguchi H,Hada E,Kobayashi K

更新日期：2007-09-01 00:00:00

abstract：:1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma. The drugs were given orally at 2--4 days intervals for a total of ten doses. 5-FU wa...

journal_title：Cancer chemotherapy and pharmacology

authors： Tsuruo T,Iida H,Naganuma K,Tsukagoshi S,Sakurai Y

更新日期：1980-01-01 00:00:00

abstract：:Previously, we showed that 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (DMC), isolated from the buds of Cleistocalyx operculatus, significantly inhibited the growth of human liver cancer SMMC-7721 cells and could induce SMMC-7721 cells apoptosis in vitro. Here, we report the antitumor effects of DMC in vivo, usi...

journal_title：Cancer chemotherapy and pharmacology

authors： Ye CL,Liu JW,Wei DZ,Lu YH,Qian F

更新日期：2005-05-01 00:00:00

abstract：:Tumor-tissue and plasma concentrations of platinum were studied prospectively in two groups of eight patients who were suffering from advanced non-small-cell lung cancer. Treatments including two different schedules of cisplatin administration (25 vs 100 mg/m2 on day 1) were compared. At 30 min after the beginning of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Pujol JL,Cupissol D,Gestin-Boyer C,Bres J,Serrou B,Michel FB

更新日期：1990-01-01 00:00:00

abstract：BACKGROUND:Aprepitant is a selective neurokinin-1 receptor antagonist that is effective for the prevention of nausea and vomiting caused by highly emetogenic chemotherapy. In vitro, aprepitant is a moderate inhibitor of the CYP3A4 enzyme, which is involved in the clearance of several chemotherapeutic agents. In this st...

journal_title：Cancer chemotherapy and pharmacology

authors： Nygren P,Hande K,Petty KJ,Fedgchin M,van Dyck K,Majumdar A,Panebianco D,de Smet M,Ahmed T,Murphy MG,Gottesdiener KM,Cocquyt V,van Belle S

更新日期：2005-06-01 00:00:00